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Abstract
Hereditary hearing loss (HHL) and age-related hearing loss (ARHL) are two major sensory diseases affecting millions of
people worldwide. Despite many efforts, additional HHL-genes and ARHL genetic risk factors still need to be identiﬁed. To
ﬁll this gap a large genomic screening based on next-generation sequencing technologies was performed. Whole exome
sequencing in a 3-generation Italian HHL family and targeted re-sequencing in 464 ARHL patients were performed. We
detected three variants in SPATC1L: a nonsense allele in an HHL family and a frameshift insertion and a missense variation
in two unrelated ARHL patients. In silico molecular modelling of all variants suggested a signiﬁcant impact on the structural
stability of the protein itself, likely leading to deleterious effects and resulting in truncated isoforms. After demonstrating
Spatc1l expression in mice inner ear, in vitro functional experiments were performed conﬁrming the results of the molecular
modelling studies. Finally, a candidate-gene population-based statistical study in cohorts from Caucasus and Central Asia
revealed a statistically signiﬁcant association of SPATC1L with normal hearing function at low and medium hearing
frequencies. Overall, the amount of different genetic data presented here (variants with early-onset and late-onset hearing
loss in addition to genetic association with normal hearing function), together with relevant functional evidence, likely
suggest a role of SPATC1L in hearing function and loss.
Introduction
Hereditary hearing loss (HHL) is the most common sen-
sory disorder and can be differentially classiﬁed according
to age of onset (congenital or acquired), type (conductive,
sensorineural or mixed) and presence of other clinical
features (syndromic or non-syndromic) [1]. It is a char-
acterized by an unparalleled genetic heterogeneity and to
date, more than 95 genes and 158 loci have been asso-
ciated with non-syndromic hearing loss (NSHL), which
accounts for the vast majority of HHL cases (http://
hereditaryhearingloss.org/). As regards age-related hear-
ing loss (ARHL), a multifactorial disorder and the most
common sensory impairment in the elderly, an exiguous
number of genes (identiﬁed using genome-wide associa-
tion studies (GWAS) and animal models [2–6]) has been
hypothesized as causative [7]. To date, only few studies
showed the presence of genes/proteins that group into
common pathways of inner ear function and loss and that
are probably involved in both early-onset HHL and
ARHL phenotypes (e.g., CDH23 gene, associated with
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ARHL, NSHL and Usher syndrome 1D) [8]. Identifying
other genetic elements causative of both early-onset and
late-onset HL would be extremely valuable for a better
understanding of the molecular mechanisms regulating
hearing function. Herein we describe SPATC1L, encoding
speriolin-like, a protein of unknown function, as likely
involved in early-onset HHL, ARHL and normal hearing
function.
Materials and methods
Prior to study onset, approval was obtained from the
Institutional Review Board of IRCCS Burlo Garofolo,
Trieste, Italy. Consent forms for clinical studies were signed
by each participant and all research was conducted
according to the ethical standards as deﬁned by the Helsinki
Declaration. Genomic DNA for sequencing and genotyping
was extracted from peripheral blood or saliva using QIA-
symphony instrument (Qiagen) and the Oragene kit (DNA
Genotek Inc.), respectively. DNA was quantiﬁed using
Nanodrop ND-1000 spectrophotometer (NanoDrop Tech-
nologies) and checked on a 0.8% agarose gel, stained with
ethidium bromide.
Subjects
HHL family
An Italian family affected by early-onset HHL was enrolled
in this study (Fig. 1a). Pure-tone audiometry and careful
clinical evaluations of all patients were conducted. A
detailed phenotypic description is reported in Supplemen-
tary S1.
Fig. 1 Pedigree and clinical features of the family and of the two
ARHL patients. a Pedigree and audiograms of the Italian family car-
rying a stop variant in SPATC1L. Filled symbols represent affected
individuals. b Audiograms of patients Arhl_1 and Arhl_2: the down-
ward slope indicates that high frequencies are severely affected
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ARHL patients
A cohort of 464 ARHL patients, derived from inbred (Friuli
Venezia Giulia-FVG- Cohort, Carlantino Cohort) and
outbred (Milan, Naples, Trieste) Italian populations, was
analysed by targeted re-sequencing (TRS). This cohort
consists of 258 males and 206 females, all of whom were
over 50 years old and who had high-frequency bilateral HL
that developed around the 5th decade of life. No defects of
the external or middle ear, nor any vestibular problem or
syndromic feature, were present.
Population-based cohort
DNA samples and phenotypic data of 604 healthy people
from several rural communities located along the Silk Road
countries were collected [9] (Figure S1). Audiometric tests
and a clinical examination were carried out for each indi-
vidual, as described in Supplementary S1.
Matched control samples
Whole genome sequencing data of 1071 healthy individuals
(43% males, 57% females) from different Italian genetic
isolates (INGI-Italian Network of Genetic Isolates) were
used as an internal database. Among them, 113 subjects
were used as controls for ARHL (individuals aged >50 y.o.
with pure tone average (PTA) at the high frequencies
<25 dB).
Genetic analysis
HHL family
To reveal the genetic cause of HHL in the Italian family
enrolled in this study (negative for variants in GJB2, GJB6
and MTRNR1), subjects were ﬁrst screened for 96 deafness-
genes using our TRS (Targeted Resequencing) protocol
[10]. Subjects I:2, II:1, II:2, II:3, II:4 and III:1 were then
selected for whole exome sequencing (WES), carried out
using the Ion ProtonTM platform (Life-Technologies).
Brieﬂy, 1 μg of genomic DNA was used to construct DNA
libraries using the Ion AmpliSeqTM Exome Kit. Libraries
were sequenced with the Ion ProtonTM System (Life-
Technologies), according to the manufacturer’s protocols.
Read mapping and variant calling were performed using Ion
TorrentSuite v4.0 software (Life-Technologies). Single
nucleotide variants (SNVs) and small insertion and dele-
tions (INDELs) were assessed using Variant Call Format
(VCF) version 4.1 [11]. SNVs and INDELS were annotated
with ANNOVAR [12] and ﬁltered using exclusion criteria
described in Figure S2. We then manually investigated the
raw sequence reads for all the candidate variants using the
Integrative Genomics Viewer (IGV) [13] to exclude false
positive calls due to read misalignment. Finally, SNVs/
INDELs that passed the ﬁltering process were analysed by
Sanger sequencing on a 3500 Dx Genetic Analyzer (Life-
Technologies), using ABI PRISM 3.1 Big Dye terminator
chemistry (Life-Technologies).
ARHL patients
A total number of 46 ARHL-candidate genes, including
SPATC1L (NC_000021.8), were sequenced using Ion Torrent
PGM™ (Life-Technologies). Genes were selected according
to data from: (a) GWAS meta-analyses on isolated and
outbred populations of European and Asian ancestry [4–6,
14], (b) literature updates and (c) animal models (unpublished
data). The full list of genes with relevant references is avail-
able in Table S1. A total number of 464 ARHL patients have
been analysed by TRS. Brieﬂy, 10 ng of genomic DNA was
used to construct DNA libraries using Ion AmpliSeq Library
Kit 2.0 (Life-Technologies). Template ion sphere particles
were prepared using Ion PGM Template OT2 200 kit and a
single end 200 base-read sequencing run was carried out
using Ion PGM sequencing 200 kit v2 (Life-Technologies),
on Ion Torrent PGM (Life-Technologies). Ten indexed
patients’ libraries were sequenced simultaneously on each Ion
318 Chip. Sequencing data were then analysed according to
the Ion Torrent SuiteTM v3.6; SNVs and INDELs were col-
lected into a standardized VCF version 4.1 and ﬁltered
according to criteria described in Figure S2. Variants were
classiﬁed as ultra-rare (minor allele frequency (MAF < 0.001),
rare (MAF < 0.01) or common (MAF > 0.01) based on fre-
quencies reported in public databases. Finally, variants that
most likely affect protein function (i.e., rare and ultra-rare
variants predicted as damaging by all in silico predictor tools)
were analysed by Sanger sequencing and tested in controls.
Protein modelling and molecular dynamics
simulations
The protein structure of human speriolin-like
(SPC1L_HUMAN) was constructed using UniProt
sequence (UniProt ID: Q9H0A9). Because no homologous
structures are available for modelling, a new structure was
built by applying iterative threading assembly reﬁnement
[15]. The quality of the wild-type model was assessed by
methods previously reported [16]. In order to produce the
mutants, Discovery studio (Accelrys Inc.) was used [17].
Wild-type and mutant proteins were used in the GRO-
MACS simulation package to prepare molecular dynamics
(MD) simulations by applying GROMOS96 force ﬁeld
[18–20]. Proteins were solubilized in the water model of
SPC3 in a cubic box with a size of 1.5 nm [20]. The systems
were neutralized by adding counter ions, and periodic
72 A. Morgan et al.
boundary conditions were applied in all directions. The
resulting systems contained from ~52,000 atoms to ~88,000
atoms. For long-range interactions, a twin range cut-off was
used: 0.8 nm for van der Waals and 1.4 nm for electrostatic
interactions. The LINCS [21] algorithm was used to con-
strain all bond lengths. To constrain the geometry of water
molecules, the SETTLE [22] algorithm was applied. The
systems were subjected to energy minimization using the
steepest descent algorithm with the tolerance of 2000 Kj/
mol/nm followed by 100 ps pre-equilibration and 10 ns of
production MD simulations. This is with a time‐step of 2 fs
at constant temperature (300 K), pressure (1 atm) and a
number of particles, without any position restraints [23]. At
every 100 ps, a structural snapshot was collected and the
tools available within GROMACS were used for analysing
the collected trajectories. The cluster analysis was utilized
to select the representative structures from MD simulations.
Each simulation produced 10,000 structures that were all
grouped into clusters based on their structural deviation, in
which the top-ranked cluster was chosen for representation,
as it is a frequently occurring conﬁrmation. The PyMOL
package (www.pymol.org) was used for all the graphical
representations. Sequence alignment of SPC1L_HUMAN
with mouse speriolin (SPERI_MOUSE) (UniProt ID:
Q148B6) was performed using ClustalO (http://www.clusta
l.org/).
In vitro molecular cloning
The impact of the identiﬁed variants on mRNA and protein
levels was tested by transient transfection in Hek293 cells
using expression clones containing either the wild-type or
the mutant cDNA. cDNAs were cloned into a pCMV6-
Entry vector (Origene), which was Myc-tagged. Forty-eight
hours after transfection total cell proteins and RNAs were
prepared and analysed by Western blot and quantitative
Real-Time PCR (qRT-PCR), respectively.
Western blot analysis and quantitative real-time PCR (qRT-
PCR)
Hek293 cells were lysed in IPLS buffer (50 mM Tris-HCl
pH7.5, 120 mM NaCl, 0.5 mM EDTA and 0.5% Nonidet P-
40) supplemented with protease inhibitors (Roche). After
sonication and pre-clearing, protein lysate concentration
was determined by Bradford Assay (Biorad). An 8%
polyacrylamide gel was used for protein electrophoresis.
After blotting, membranes were blocked with 5% skim milk
in Tris-buffered saline, 0.1% Tween 20 (TBST) and then
incubated overnight with primary c-Myc Antibody 9E10
monoclonal (Santa Cruz) and HSP 90 monoclonal (Santa
Cruz). Secondary antibodies (anti-mouse antibody (Santa
Cruz)) were diluted in blocking buffer and incubated with
the membranes for 45 min at room temperature. Proteins
were detected with the ECL detection kit (GE Health Care
Bio-Sciences). Housekeeping proteins were used as an
internal control for protein loading as well as for reference
in the western blotting analysis. RNA was extracted from
cell pellets using a High Pure RNA Isolation Kit (Roche).
Total RNA (1 μg) was reverse transcribed using Tran-
scriptor First Strand cDNA Synthesis kit (Roche). qRT-
PCR was performed using standard PCR conditions in a
7900HT fast real-time PCR System (Applied Biosystems)
with Power SYBR Green PCR Master Mix (Thermo Fisher
Scientiﬁc). Gene-speciﬁc primers were designed with Pri-
mer3Web software (http://bioinfo.ut.ee/primer3/) (Myc_-
For: 5′ AGCAGAAACTCATCTCAGAAG 3′; SPA
TC1L_human_cells_Rev: 5′ CGTGAACCTTCCGAAAT
CTG 3′). Expression levels were standardized to Neo gene
expression and data were analyzed using the 2–ΔΔCT
Livak Method [24]. All experiments were performed in
biological triplicates.
Candidate gene association study
DNA samples (n= 604) were genotyped with the Illumina
Exome Chip. The analysis focused on functional SNPs
belonging to the coding region of SPATC1L. Variant calling
was reﬁned using zCall [25], and quality control ﬁlters were
applied taking into account standard parameters such as call
rate > 0.99, Hardy-Weinberg equilibrium (p < 1e-08) and
heterozygosity (FDR < 0.01). A candidate gene association
study was performed for three different PTAs on common
variants only (MAF > 0.01). Outliers, deﬁned as subjects
being more than three standard deviations from the mean of
the phenotypic distribution, were excluded from the ana-
lysis. To account for population structure and relatedness, a
linear mixed model with sex and age as covariates and the
kinship matrix as the random effect was applied. The kin-
ship matrix was computed over the whole set of available
common SNPs (total ~80,000).
SPATC1L tissue expression
Total RNA samples were extracted from wild-type CD1
mouse whole cochleae at post-natal day 3 (P3), P8, P12 and
2 month-old. Moreover, total RNA from different tissues
including liver, spleen, lung, kidney, brain, testis and heart
was extracted from 2-month old mice. The extraction was
made using Direct-zol RNA MiniPrep Kit (Zymo
Research). RNA was quantiﬁed using Nanodrop ND-1000
(NanoDrop Technologies). cDNAs were generated from
5 μg of total RNA using the Transcriptor First Strand cDNA
Synthesis Kit (Roche) and were used for semi-quantitative
RT-PCR (sqRT-PCR). Six microlitres of the RT products
were used for PCR ampliﬁcation. Gene-speciﬁc primers
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were designed with Primer3Web software (SPATC1L_1-
For: TACCTCAATGAGATCCAGAG; SPATC1L_1Rev:
AACACATAGGCCAGGATACG). PCR reactions
were optimized to 95 °C for 2 min, 30 ampliﬁcation cycles
at 95 °C for 10 s, 60 °C for 15 s, 72 °C for 4 s and a ﬁnal
extension of 1 min at 72 °C using Kapa HiFi HotStart
ReadyMix PCR kit (Kapa Biosystem). Ampliﬁed products
were checked on 2% agarose gels and visualized by ethi-
dium bromide staining. β-Actin was used as internal control.
Experiments were performed in biological triplicates.
Results
Familial HHL
In this study, an Italian family, displaying bilateral sensor-
ineural symmetric progressive moderate-severe to profound
hearing loss (Fig. 1a) was analysed by TRS and WES. TRS
did not reveal any disease-causing variant (Supplemen-
tary S2). The overall mean-depth base coverage for WES
was 108×, while on average 89% of the targeted region was
covered at least 20-fold. A total of 91,597 variants were
called among the six subjects included in the study. After
variant ﬁltering, we identiﬁed eight candidate SNVs. Three
of them were excluded because of their frequency in our
internal sequencing database (i.e., NGS data from over 1071
unrelated individuals). The remaining ones (Table S2) have
been prioritized according to: (1) role of the gene based on
literature research, (2) type of variant, and (3) segregation
within the family. Four missense variants affecting
genes already known to be associated with speciﬁc
syndromes [26, 27] or with other traits not present in any
of the affected members [28–30] were excluded from
the analysis. The remaining nonsense variant, c.846C>G
(NM_001142854.1), was present in SPATC1L
(NC_000021.8) and leads to a premature stop codon with
the loss of the last 58 amino acids of the protein
(p.(Tyr282*)). This variant was not described in any public
database and was not present in our internal database.
Sanger sequencing demonstrated the correct segregation of
this allele within the family (Figure S3A).
Screening of SPATC1L in ARHL cases
TRS data of 464 ARHL patients were produced. A mean of
33.5 megabases of raw sequence data were available for each
subject. The coverage, on 95% of the targeted region, was at
least 20-fold, with a 270 fold mean-depth total coverage. On
average 333 SNVs/INDELs were called for each patient. In
particular, a frameshift duplication, c.340_343dupTTCA
(p.(Lys115Ilefs*12)) (NM_001142854.1), was detected in
Arhl_1 patient (70 y.o.), coming from Carlantino (an isolated
village from Southern Italy) and showing moderate to pro-
found HL (Fig. 1b). In this case, the availability of extended
pedigrees allowed us to look for segregation of this allele in
other family members. Despite the fact that we are dealing
with a late onset disease where frequently there are no other
living family members, we conﬁrmed the absence of this
variant in the only living, aged and healthy family member
(i.e., ﬁrst cousin aged 68 years old). A second allele, a mis-
sense variant c.656A>C (p.(Tyr219Ser)) (NM_001142854.1)
was detected in patient Arhl_2 (55 y.o.), coming from Milan
(Italy) and showing moderate to severe HL (Fig. 1b).
Unfortunately, no living relatives were available for segre-
gation analysis. All in silico predictor tools classiﬁed this
allele as damaging. Both alleles were conﬁrmed by Sanger
sequencing (Figure S3B) and were the only ultra rare variants
likely affecting protein function present in Arhl_1 and Arhl_2
cases. In particular, the c.340_343dupTTCA allele was
described only in the gnomAD browser, with a MAF of
0.00001923, while the c.656A>C variant has never been
reported. Moreover, both variants were not present in our
internal database of NGS data.
All SPATC1L variants are available in the European
Genome-Phenome Archive (EGA) database (https://ega-a
rchive.org/studies/EGAS00001003047).
Molecular modelling of protein
To identify functional domains and to assess further the
possible role of the speriolin-like protein, its sequence was
compared to that of its paralog of known function, speriolin.
In particular SPC1L_HUMAN and SPERI_MOUSE were
compared (Fig. 2a). Sequence alignment shows a 70%
sequence similarity with 129 identical residues. In SPER-
I_MOUSE the most conserved regions correspond to the N-
and C-terminal regions that contain important functional
domains, i.e., the leucine zipper and the binding region for
cell division cycle protein 20 (Cdc20), respectively.
According to sequence similarity, these domains are most
likely present also in the human speriolin-like protein.
Interestingly, all variants identiﬁed in our patients affect the
C-terminus; in particular, c.656A>C (p.(Tyr219Ser)) occurs
in a highly conserved region (RLYGFTV) while c.846C>G
(p.(Tyr282*)) and c.340_343dupTTCA (p.(Lys115I-
lefs*12)) cause the partial and total loss of this region,
respectively. The impact of all variants was analysed by
MD simulations with the representative structures. As
expected, the wild-type showed a stable behaviour by
maintaining secondary structures (Fig. 2d–g), while all
mutants displayed abnormal behaviours. Overall MD of the
SPC1L_HUMAN systems demonstrated: (a) reduced
structural stability for the c.846C>G (p.(Tyr282*)) mutant
in addition to the loss of part of the C-terminus (283–340)
and mild alteration of the secondary structures at the
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N-terminus; (b) reduced structural stability for the
c.340_343dupTTCA (p.(Lys115Ilefs*12)) mutant plus loss
of ~75% of the protein leading to an abnormal protein
isoform; (c) increased structural stability and rigidity for the
c.656A>C (p.(Tyr219Ser)) mutant and slight conforma-
tional changes nearby the mutational spot.
In vitro molecular cloning
To investigate further the effect of SPATC1L variants on
mRNA and protein levels, expression vectors containing
either the wild-type SPATC1L cDNA or the mutant ones
were used. qRT-PCR didn’t reveal any signiﬁcant differ-
ence in the expression levels of all mutants compared to
wild type (Fig. 3a). Western blot analysis conﬁrmed the
presence of all mutated protein isoforms (Fig. 3b). In par-
ticular, in the case of the missense variant of the Arhl_2
patient, c.656A>C (p.(Tyr219Ser)), a full-length protein
was detected. On the contrary, in the case of the two
truncating variants carried by the Arhl_1 patient and by the
Italian family (c.340_343dupTTCA (p.(Lys115Ilefs*12))
and c.846C>G (p.(Tyr282*)) respectively), shorter protein
isoforms were observed.
Genetic association and expression studies
To investigate further the role of SPATC1L in hearing, a
candidate gene association analysis in a healthy and com-
pletely independent cohort coming from the Caucasus and
Central Asia (Silk Road) (https://www.ebi.ac.uk/ena/data/
view/PRJEB7469) was performed. After ﬁltering for quality
parameters and MAF, only 3 SNPs (rs14378, rs113710653
and rs113146399) located in the SPATC1L coding region
were available for the analysis. Results, including size
estimates and p-values for each SNP and trait, are shown in
Table 1. Statistically signiﬁcant associations with 3
SPACT1L SNPs, were obtained for pure tone average of
low frequencies (PTAL) (i.e., 0.25, 0.5 and 1 kHz),
Fig. 2 Sequence analysis and molecular modelling of the proteins.
a Sequence alignment of human Speriolin-like protein (SPC1L_
HUMAN, UniProt ID: Q9H0A9) with mouse Speriolin (SPERI_
MOUSE, UniProt ID:Q148B6). b Molecular model of the human
speriolin-like protein with potential functional regions. c Average radius
of gyration of the four systems. d–g Representative structures of the
wild type, c.846C>G (p.(Tyr282*)), c.340_343dupTTCA (p.(Lys115I-
lefs*12)) and c.656A>C (p.(Tyr219Ser)) respectively, from molecular
dynamics simulations. Here, the locations of the variants are represented
as red sticks
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(rs14378, p= 0.031556621; rs113710653, p=
0.005643919; rs113146399, p= 0.026677654) and PTA of
middle frequencies (PTAM) (i.e., 0.5, 1 and 2 kHz)
(rs14378, p= 0.04347863; rs113710653, p= 0.00802626;
rs113146399, p= 0.03660835). A boxplot of PTAL resi-
duals for the three genotypes of the most associated SNP
Fig. 3 SPATC1L mRNA and protein levels in Hek293 transfected cells
and Spatc1l expression in mouse whole cochlea and other tissues at
different time points. a qRT-PCR analysis of relative mRNA expres-
sion of SPATC1L wild type and mutants after 48 h of transfection in
Hek293 cells. Results are expressed as a fold-change of expression
levels, and are normalized to the relative amount of the internal
standard Neo. Error bars indicate 95% conﬁdence intervals. b Western
blot analysis of SPATC1L wild type and mutant proteins. Hsp90 was
applied to determine equal loading. c The graph shows expression of
Spatc1l in mouse whole cochlea at P3, P8, P12 and 2 months. Results
are reported as fold change in gene expression over β actin, used as an
internal control. The gene shows an age-related expression. d The
graph shows Spatc1l expression at 2 months of age in different mouse
tissues, including liver, cochlea, spleen, lung, kidney, brain, testis and
heart. Results are reported as fold change in gene expression over β
actin, used as an internal control
Table 1 Results of the candidate gene association analysis
Trait SNP Chr Position Effect allele Other allele Eff. all. freq N Beta SE beta P-value
PTAL rs14378 21 47581423 T C 0.054 598 0.05334218 0.02481052 0.031556621
PTAL rs113710653 21 47581835 T C 0.039 590 0.07971061 0.02879945 0.005643919
PTAL rs113146399 21 47581949 T C 0.044 598 0.06031144 0.02721387 0.026677654
PTAM rs14378 21 47581423 T C 0.054 597 0.06057786 0.03000266 0.04347863
PTAM rs113710653 21 47581835 T C 0.040 589 0.09218281 0.03477333 0.00802626
PTAM rs113146399 21 47581949 T C 0.044 597 0.06870397 0.03287106 0.03660835
PTAH rs14378 21 47581423 T C 0.054 604 0.006119463 0.04790555 0.8983546
PTAH rs113710653 21 47581835 T C 0.039 596 0.02570644 0.05588673 0.6455349
PTAH rs113146399 21 47581949 T C 0.044 604 −0.004327187 0.05277132 0.9346476
PTAL pure tone average of low frequencies, PTAM pure tone average of medium frequencies, PTAH pure tone average of high frequencies, Eff. all.
freq effect allele frequency, Beta effect size estimate, SE Beta effect size standard error
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(rs113710653, p= 0.00564) is given in Figure S4. Indivi-
duals carrying the alternative allele have worse hearing,
taking into account sex and age differences. In particular,
homozygous TT subjects show at PTAL and PTAM an
increased dB threshold (+2.3 dB and 3.27 on average
respectively) compared to the wild type (CC) ones (OR=
1.17, 95% CI= [1.05–1.31] for PTAL and OR= 1.20, 95%
CI= [1.05–1.38] for PTAM). None of these SNPs match
with any known eQTL region, according to the GTex
Database (http://www.gtexportal.org/home/). To support
further the genetic results, gene expression studies on CD1
mice were performed. These studies revealed the expression
of Spatc1l in mouse whole cochlea increasing with age from
P3 to P12 (Fig. 3c), which corresponds to the development
of auditory perception. Public databases, i.e., SHIELD
(https://shield.hms.harvard.edu/index.html), gEAR (http://
gear.igs.umaryland.edu/) and Mouse Genome Informatics
(MGI) (http://www.informatics.jax.org/), conﬁrmed gene
expression in mouse inner ear, even though at low levels. In
particular, according to SHIELD, Spatc1l is more abun-
dantly expressed in hair cells compared to non-hair cells
during mouse inner ear development, and in adult mice it is
more expressed in cochlear outer hair cells compared to
inner hair cells. Finally it is also detected in the vestibular
and spiral ganglion at different developmental stages. In
agreement with literature data, Spatc1l expression was also
detected in brain and testis from 2 month-old mice (Fig. 3d).
Discussion
Here we propose, for the ﬁrst time, the involvement of
SPATC1L in hearing function and loss. SPATC1L encodes
two different isoforms of the speriolin-like protein, whose
function is still unknown. A study from Lecat et al. [31],
revealed that SPC1L_HUMAN localises in the cytoplasm,
in the nucleus and in the perinuclear region in Hek293 cells,
and after activation of the NK2 receptor it moves to cellular
junctions, suggesting a possible role of this protein in cel-
lular junction formation. One major type of cell junctions
are gap junctions, existing extensively in different parts of
the cochlea and having many functions herein [32]. To date,
apart from the role of connexins, little is known about
functions of other proteins in cellular junctions. Considering
the relevance of these cellular components in hearing
function, the role of SPATC1L and other related proteins
warrants further investigation. It has also been shown that
SPATC1L modulates the response of human cells to alky-
lating agents, having a protective effect. Thus, decreased
gene expression correlates with an increased sensitivity to
alkylating agents, such as N-methyl-N’-nitro-N-nitroso-
guanidine (MNNG) [33]. Further investigations on how
SPATC1L plays this role will help in understanding if it is
involved in processes that guarantee cell survival in
response to damaging agents or oxidative stress, a presumed
major cause of ARHL and hearing dysfunction. Accord-
ingly, some ARHL candidate genes are involved in oxida-
tive stress response and mitochondrial dysfunction [34]. In
order to test the effect of all SPATC1L variants, MD
simulations were performed. Overall MD suggested that all
mutated alleles affect protein stability and secondary
structural elements, which are essential for protein function
[35-39]. In particular, we observed severe structural chan-
ges leading to incomplete isoforms, with partial or entire
loss of the C-terminus (i.e., c.340_343dupTTCA (p.
(Lys115Ilefs*12)) and c.846C>G (p.(Tyr282*)) mutants),
while for the c.656A>C (p.(Tyr219Ser)) mutant a dis-
turbance of a highly conserved region of the C-terminus and
an increased structural rigidity were observed. Considering
that the C-terminus of SPC1L_HUMAN contains important
functional domains, the loss/alteration of this region might
be highly deleterious. The impact of all variants was also
evaluated by in vitro molecular cloning. In particular,
Western blot analysis revealed the presence of all mutated
protein isoforms that, according to our protein modelling
results, are likely to be dysfunctional, thus leading to altered
protein function. Interestingly, in the case of the frameshift
duplication (patient Arhl_1), two different bands were
detected: a higher one, with the expected molecular weight,
and a smaller one. Considering the huge impact of this
variant on protein structure, it is highly probable that the
truncated isoform will be rapidly degraded, thus the shorter
band detected at Western blot analysis may represent a
pattern of protein degradation. Moreover, results from
expression studies reveal that SPATC1L expression increa-
ses during developmental stages in hearing and then it
remains stable until adult age, suggesting its possible
involvement in the development and maintenance of the
auditory system. A remarkable expression was also detected
in both brain and testis indicating a possible role also in
these tissues despite the absence of any clinical symptoms
related to these two organs in the cases reported herein.
Considering all these ﬁndings, our hypothesis suggests that
these variants can lead to slightly different phenotypes. In
fact, the severe to profound phenotype in the HHL patients
is due to a nonsense allele causing a reduced stability and
integrity of the protein and affecting both isoforms of the
gene, thus leading to more deleterious consequences.
Accordingly, a similar severe phenotype was present in the
ARHL patient carrying another disruptive allele (i.e., the
frameshift duplication) despite affecting the coding region
of only one of the two isoforms. As expected, a milder
phenotype is due to the presence of the missense variant in
the second ARHL patient. In conclusion, the amount of
genetic data presented herein, together with functional and
expression data, plus an interesting genotype–phenotype
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correlation, suggest a role of SPATC1L in the auditory
system.
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